On June 1, 2024, BioNTech SE and Genmab A/S announced initial data from a Phase 2 trial of acasunlimab, showing promising results for patients with metastatic non-small cell lung cancer (mNSCLC). This filing signals a significant advancement in their cancer treatment pipeline.